Drug company Apotex Health Corp. is increasing the size of its initial public offering to about $1.3 billion, up from its earlier plan for $1 billion.
The company says it now plans an offering of between 54.17 million and 65 million shares at a price per share between $20.00 and $24.00, compared with an earlier plan for 41.67 million and 50 million shares in the same price range.
The treasury offering of shares under the plan is unchanged at between 35.42 million and 42.5 million shares, however a secondary offering by certain shareholders has been increased to between 18.75 million and 22.5 million shares.
The earlier secondary offering had called for the sale of between 6.25 million and 7.5 million shares.
The selling shareholders are also expected to grant an over-allotment option to the underwriters for up to an additional 8.13 million to 9.75 million shares at the offering price, up from an earlier over-allotment option for an additional 6.25 million to 7.5 million shares.
Apotex has a broad portfolio of generic drugs and consumer health products.
This report by The Canadian Press was first published June 10, 2026.
